Introduction to Matching Adjusted Indirect Comparisons in CLL Treatment

Dr. Mazyar Shadman from the University of Washington and Fred Hutchinson Cancer Center and Dr. Danielle Brander from Duke Cancer Institute introduce their discussion on interpreting matching adjusted indirect comparisons (MIACs) to inform first-line chronic lymphocytic leukemia (CLL) treatment decisions. The focus centers on how recent comparative analyses help clinicians choose between continuous BTK inhibitor therapy versus fixed-duration venetoclax-based therapies in clinical practice.

Dr. Brander explains that MIACs, while not replacing direct in-trial comparisons and having inherent limitations, provide systematic and statistical approaches for situations lacking randomized trials. These comparisons utilize patient-level data from one trial compared with aggregate population data from a second trial. Two main types exist: anchored comparisons where both trials share similar comparison arms, providing advantages in making comparisons, and unanchored approaches requiring adjustment or matching of trial populations.

In CLL and other hematologic malignancies, where treatment options evolve rapidly, MIACs offer opportunities for additional comparisons beyond limitations of avoiding mismatched trial-to-trial comparisons. Dr. Shadman emphasizes understanding where this methodology stands in evidence-based medicine hierarchy, never replacing randomized head-to-head trials but providing valuable information when such trials are unavailable due to faster drug development pace than evidence generation. He stresses considering MIACs as supplemental information alongside clinical trial data, real-world evidence, and individual patient and disease characteristics, while paying attention to eligibility criteria, study timing, and methodology transparency across different analytical scenarios.